Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia

  • Mohd Arifin Kaderi
  • Mahmoud Mansouri
  • Norafiza Zainuddin
  • Nicola Cahill
  • Rebeqa Gunnarsson
  • Mattias Jansson
  • Eva Kimby
  • Anna Aleskog
  • Jeanette Lundin
  • Bengt Glimelius
  • Mads Melbye
  • Gunnar Juliusson
  • Jesper Jurlander
  • Richard Rosenquist
Publiceringsår: 2010
Språk: Engelska
Sidor: 335-339
Publikation/Tidskrift/Serie: Leukemia Research: A Forum for Studies on Leukemia and Normal Hemopoiesis
Volym: 34
Nummer: 3
Dokumenttyp: Artikel i tidskrift
Förlag: Elsevier


The 309T>G polymorphism in the promoter region of the MDM2 gene, known as SNP309, has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. To investigate this further, we analyzed the MDM2 SNP309 genotypes in 418 CLL patients and correlated the results with established CLL prognostic factors, time to treatment and overall survival. In this Swedish cohort, no association existed between any particular MDM2 SNP309 genotype, overall survival and time to treatment. Furthermore, no correlation was shown between the MDM2 SNP309 genotypes and Binet stage, IGHV mutational status and recurrent genomic aberrations. In summary, this study argues against the use of the MDM2 SNP309 as a prognostic marker in CLL. (C) 2009 Elsevier Ltd. All rights reserved.


  • Cancer and Oncology
  • Genomic aberrations
  • Prognostic markers
  • status
  • IGHV mutational
  • Binet stage
  • MDM2 SNP309
  • Chronic lymphocytic leukemia


  • ISSN: 1873-5835

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen